Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.42 |
| ▸ | JAK1 | P23458 | 8/20 | 0.42 |
| ▸ | JAK3 | P52333 | 8/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.34 |
| ▸ | UGCG | Q16739 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1369630 | 0.89 | JAK3 (0.52) | JAK2JAK1JAK3 | |
| SCHEMBL1371189 | 0.84 | JAK2 (0.57) | JAK2JAK1JAK3 | |
| SCHEMBL1353887 | 0.81 | JAK2 (0.39) | JAK2JAK1JAK3 | |
| SCHEMBL1351068 | 0.81 | DGAT1 (0.40) | JAK2JAK1JAK3NPC1 | |
| SCHEMBL1369633 | 0.80 | JAK2 (0.39) | JAK2JAK1JAK3 | |
| SCHEMBL1353886 | 0.80 | CNR2 (0.43) | JAK2JAK1JAK3 | |
| SCHEMBL1696870 | 0.79 | DGAT1 (0.40) | JAK2JAK1JAK3 | |
| SCHEMBL1368957 | 0.78 | JAK3 (0.58) | JAK2JAK1JAK3 | |
| SCHEMBL2344237 | 0.78 | DGAT1 (0.38) | JAK2JAK1JAK3 | |
| SCHEMBL1371282 | 0.77 | DGAT1 (0.40) | JAK2JAK1JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011117145-A2 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-09-29 | — | — | WO | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | JAK2 5/4885JAK1 6/4885JAK3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.